Compare GTLB & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTLB | LIVN |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 2021 | 2015 |
| Metric | GTLB | LIVN |
|---|---|---|
| Price | $21.58 | $63.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 7 |
| Target Price | $40.96 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 6.3M | 757.9K |
| Earning Date | 03-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $955,224,000.00 | N/A |
| Revenue This Year | $18.82 | $9.43 |
| Revenue Next Year | $15.95 | $6.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.81 | N/A |
| 52 Week Low | $20.20 | $32.48 |
| 52 Week High | $52.38 | $71.58 |
| Indicator | GTLB | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 51.32 |
| Support Level | N/A | $61.80 |
| Resistance Level | $50.49 | $65.25 |
| Average True Range (ATR) | 0.98 | 2.11 |
| MACD | 0.18 | 0.15 |
| Stochastic Oscillator | 34.99 | 85.98 |
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.